ENTITY
SK Biopharmaceuticals

SK Biopharmaceuticals (326030 KS)

174
Analysis
Health Care • South Korea
SK Biopharmaceuticals Co., Ltd. researches and develops new drugs. The Company develops and markets brain disorders treatment drugs, central nervous system disorders treatment drugs, and other products. SK Biopharmaceuticals markets its products worldwide.
more
•21 Jan 2022 18:48

LG Energy Solution: Confirmed Allocations, Float, & Lock-Up Periods

The final tally for the locked-up shares of LG Energy Solution IPO is 13.6 million shares, representing 58.3% of total shares allocated for the...

Logo
679 Views
Share
•24 Dec 2021 23:19

SK Biopharmaceuticals (326030 KS): A Promising Play on Central Nervous System Disorders

SKBP's independently developed and marketed drug Xcopri has the potential to reach peak revenue of $1.5 billion in 2027. The company targets to...

Logo
618 Views
Share
•17 Dec 2021 04:57

LG Energy Solution - What Are the Locals Saying About This IPO?

The local market is generally positive on the LG Energy Solution IPO. Valuations are reasonable and many investors expect the IPO to be priced at...

Logo
665 Views
Share
bullish•Kakaopay
•21 Oct 2021 18:27

Kakao Pay Book Building Results

Maeil Business Daily reported after the market close today that Kakao Pay has successfully completed its IPO book building with the IPO price of...

Logo
471 Views
Share
bullish•SK Inc
•04 Oct 2021 20:09

SK Inc - SoTP Valuation Analysis and 3 Key Catalysts (SK E&S, SK Pharmteco, & SK Siltron)

In this insight, we provide an updated NAV valuation analysis of SK Inc. Our updated base case valuation of SK Inc is 381,838 won per share,...

Logo
498 Views
Share
x